Literature DB >> 19574485

Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer.

Allan Hackshaw, Ujjal Mallick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574485      PMCID: PMC2705272          DOI: 10.3121/cmr.2009.841

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


× No keyword cloud information.
  4 in total

Review 1.  Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.

Authors:  Suhail A R Doi; Nicholas J Woodhouse; Lukman Thalib; Adedayo Onitilo
Journal:  Clin Med Res       Date:  2007-06

2.  The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.

Authors:  U Mallick; C Harmer; A Hackshaw
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06       Impact factor: 4.126

Review 3.  Spurious precision? Meta-analysis of observational studies.

Authors:  M Egger; M Schneider; G Davey Smith
Journal:  BMJ       Date:  1998-01-10

Review 4.  131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review.

Authors:  Allan Hackshaw; Clive Harmer; Ujjal Mallick; Masud Haq; Jayne A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2006-10-10       Impact factor: 5.958

  4 in total
  1 in total

Review 1.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.